Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Lui

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
JAMA Psychiatry|July 28, 2021
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysisFelicia Ceban, Danica Nogo, Isidro P Carvalho, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Journal of Affective Disorders|June 26, 2021
Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot studyRoger S McIntyre, Yena Lee, Nelson B Rodrigues, et al.
Brain, Behavior, and Immunity|January 1, 2022
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysisFelicia Ceban, Susan Ling, Leanna M W Lui, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Brain : a Journal of Neurology|November 8, 2023
Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trialRoger S McIntyre, Lee Phan, Angela T H Kwan, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
The American Journal of Psychiatry|March 17, 2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ImplementationRoger S McIntyre, Joshua D Rosenblat, Charles B Nemeroff, et al.
Bulletin of the World Health Organization|November 12, 2020
Development and implementation of guidelines for the management of depression: a systematic reviewYena Lee, Elisa Brietzke, Bing Cao, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
JAMA Psychiatry|July 28, 2021
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysisFelicia Ceban, Danica Nogo, Isidro P Carvalho, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Journal of Affective Disorders|June 26, 2021
Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot studyRoger S McIntyre, Yena Lee, Nelson B Rodrigues, et al.
Brain, Behavior, and Immunity|January 1, 2022
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysisFelicia Ceban, Susan Ling, Leanna M W Lui, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Brain : a Journal of Neurology|November 8, 2023
Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trialRoger S McIntyre, Lee Phan, Angela T H Kwan, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
The American Journal of Psychiatry|March 17, 2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ImplementationRoger S McIntyre, Joshua D Rosenblat, Charles B Nemeroff, et al.
Bulletin of the World Health Organization|November 12, 2020
Development and implementation of guidelines for the management of depression: a systematic reviewYena Lee, Elisa Brietzke, Bing Cao, et al.
Pageof 8